Table 2.

Baseline characteristics of study patients

Cohort/ClassMen/Women (n/n)Median Age (yr)Median eGFR (ml/min per 1.73 m2)aMedian HtTKV (ml/m)bFamily History of ADPKD—Yes/No/Unknown (n/n/n)Genetic Analysis, n (%)NMD, n (%)PKD1, n (%)PKD2, n (%)Median Follow-Up SCrc (mg/dl)Median Follow-Up (yr)
MTPC
 1538 (218/320)44 (35–51)75 (45–97)668 (430–1234)430/71/37308 (57)d20 (6)e239 (78)e49 (16)e6 (4–12)6 (4–10)
 2
  A36 (21/15)60 (50–71)67 (57–80)591 (476–1020)16/14/611 (31)d5 (45)d6 (55)e 0 (0)e4 (2–8)6 (3–9)
  B16 (7/9)62 (50–70)33 (21–50)351 (248–481)9/6/12 (13)d0 (0)d2 (100)e 0 (0)e9 (2–14)8 (4–11)
CRISP
 1173 (67/106)34 (25–40)94 (80–112)492 (356–744)139/11/23171 (99)d14 (8)e 133 (78)e24 (14)e 5 (4–6)9 (8–10)
 2
  A3 (1/2)43 (38–46)52 (51–55)886 (754–1574)2/0/13 (100)d0 (0)d1 (33.3)e2 (66.7)e 59 (8–9)
  B1 (1/0)16742601/0/01 (100)d01 (100)e0510
Total767 (315/452)42 (15–80)78 (9–173)608 (141–6167)597/102/68496 (65)d39 (8)e 382 (77)e75 (15)e 6 (2–49)7 (0.5–18)
  • Medians are expressed with interquartile ranges in parentheses. NMD, no mutation detected; SCr, serum creatinine.

  • a Estimated using Chronic Kidney Disease Epidemiology equation.

  • b Calculated by ellipsoid formula.

  • c Does not include baseline SCr.

  • d Percentage is based on total number of patients for each class.

  • e Percentage is based on patients with genetic analysis within each class.